This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Takeda Pharmaceutical Company Ltd
Drug Names(s): yttrium-huJ591 and lutetium-huJ591
Description: J591 is a humanized monoclonal antibody that targets the prostate specific membrane antigen (PSMA) protein on the prostate cancer cell surface. Millennium and BZL are developing conjugates of J591 with both radioactivity (MLN591RL) and to chemotherapy (MLN2704) to make the antibody a more potent tumor cell killer. The systemic toxicities of more potent chemotherapy and radiation are minimized by the construct’s ability to specifically target cancer cells. Radioisotopes such as lutetium and yttrium have been used in patients with metastatic, hormone and chemotherapy-refractory prostate cancer.
In animal models of prostate cancer, naked J591 has demonstrated considerable efficacy. It also has been used as an imaging and therapeutic targeting agent for primary and metastatic tumors in patients with prostate and other cancers.
J591, the parent antibody of MLN2704, was developed by BZL Biologics, which partnered with Millennium in April 2001 to develop MLN591RL and other constructs that use the J591 antibody.
In April 2008, Takeda Pharmaceutical and Millennium Pharmaceuticals announced that they entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share. The acquisition closed in May 2008.
Partners: BZL Biologics, LLC
Additional information available to subscribers only: